These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 31773656)
1. High-Throughput Assessment of Metabolism-Induced Toxicity of Compounds on a 384-Pillar Plate. Kang SY; Yu KN; Joshi P; Lee MY Methods Mol Biol; 2020; 2089():191-207. PubMed ID: 31773656 [TBL] [Abstract][Full Text] [Related]
2. High-throughput metabolism-induced toxicity assays demonstrated on a 384-pillar plate. Yu KN; Kang SY; Hong S; Lee MY Arch Toxicol; 2018 Aug; 92(8):2501-2516. PubMed ID: 29974144 [TBL] [Abstract][Full Text] [Related]
3. Prediction of metabolism-induced hepatotoxicity on three-dimensional hepatic cell culture and enzyme microarrays. Yu KN; Nadanaciva S; Rana P; Lee DW; Ku B; Roth AD; Dordick JS; Will Y; Lee MY Arch Toxicol; 2018 Mar; 92(3):1295-1310. PubMed ID: 29167929 [TBL] [Abstract][Full Text] [Related]
4. Expression of drug metabolizing enzymes and transporters in the cochlea: Implications for drug delivery and ototoxicity. Kennon-McGill S; Clemens MM; McGill MR Hear Res; 2019 Aug; 379():98-102. PubMed ID: 31121337 [TBL] [Abstract][Full Text] [Related]
5. Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. Lash LH; Putt DA; Cai H Toxicology; 2008 Feb; 244(1):56-65. PubMed ID: 18055091 [TBL] [Abstract][Full Text] [Related]
6. Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer. den Braver-Sewradj SP; den Braver MW; Vermeulen NP; Commandeur JN; Richert L; Vos JC Toxicol In Vitro; 2016 Jun; 33():71-9. PubMed ID: 26921663 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. Iyanagi T Int Rev Cytol; 2007; 260():35-112. PubMed ID: 17482904 [TBL] [Abstract][Full Text] [Related]
8. The use of hepatocytes to investigate UDP-glucuronosyltransferases and sulfotransferases. Fournel-Gigleux S; Coughtrie MW; Ouzzine M; Magdalou J Methods Mol Biol; 2010; 640():309-26. PubMed ID: 20645060 [TBL] [Abstract][Full Text] [Related]
9. Estimation of bisphenol A-Human toxicity by 3D cell culture arrays, high throughput alternatives to animal tests. Lee DW; Oh WY; Yi SH; Ku B; Lee MY; Cho YH; Yang M Toxicol Lett; 2016 Sep; 259():87-94. PubMed ID: 27491884 [TBL] [Abstract][Full Text] [Related]
10. Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human. Basit A; Neradugomma NK; Wolford C; Fan PW; Murray B; Takahashi RH; Khojasteh SC; Smith BJ; Heyward S; Totah RA; Kelly EJ; Prasad B Mol Pharm; 2020 Nov; 17(11):4114-4124. PubMed ID: 32955894 [TBL] [Abstract][Full Text] [Related]
11. Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Westerink WM; Schoonen WG Toxicol In Vitro; 2007 Dec; 21(8):1592-602. PubMed ID: 17716855 [TBL] [Abstract][Full Text] [Related]
12. Modulation of metabolizing enzymes by bisphenol a in human and animal models. Quesnot N; Bucher S; Fromenty B; Robin MA Chem Res Toxicol; 2014 Sep; 27(9):1463-73. PubMed ID: 25142872 [TBL] [Abstract][Full Text] [Related]
13. A new in vitro approach for the simultaneous determination of phase I and phase II enzymatic activities of human hepatocyte preparations. Lahoz A; Donato MT; Montero S; Castell JV; Gómez-Lechón MJ Rapid Commun Mass Spectrom; 2008; 22(2):240-4. PubMed ID: 18088071 [TBL] [Abstract][Full Text] [Related]
14. Advances in drug metabolism and pharmacogenetics research in Australia. Mackenzie PI; Somogyi AA; Miners JO Pharmacol Res; 2017 Feb; 116():7-19. PubMed ID: 27956261 [TBL] [Abstract][Full Text] [Related]
15. High-Throughput and Reliable Isotope Label-free Approach for Profiling 24 Metabolic Enzymes in FVB Mice and Sex Differences. Chen J; Zhu L; Li X; Zheng H; Yan T; Xie C; Zeng S; Yu J; Jiang H; Lu L; Qi X; Wang Y; Hu M; Liu Z Drug Metab Dispos; 2017 Jun; 45(6):624-634. PubMed ID: 28356314 [TBL] [Abstract][Full Text] [Related]
16. Hepatic Metabolism of Sakuranetin and Its Modulating Effects on Cytochrome P450s and UDP-Glucuronosyltransferases. Jeong H; Lee J; Kim S; Yeo YY; So H; Wu H; Song YS; Jang CY; Kim HD; Kim MJ; Chang M Molecules; 2018 Jun; 23(7):. PubMed ID: 29949932 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. Yokoyama Y; Sasaki Y; Terasaki N; Kawataki T; Takekawa K; Iwase Y; Shimizu T; Sanoh S; Ohta S Biol Pharm Bull; 2018 May; 41(5):722-732. PubMed ID: 29445054 [TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes). Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472 [TBL] [Abstract][Full Text] [Related]
19. Inter-individual Variability in Activity of the Major Drug Metabolizing Enzymes in Liver Homogenates of 20 Individuals. den Braver-Sewradj SP; den Braver MW; van Dijk M; Zhang Y; Dekker SJ; Wijaya L; Vermeulen NPE; Richert L; Commandeur JNM; Vos JC Curr Drug Metab; 2018; 19(4):370-381. PubMed ID: 29318967 [TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Rushmore TH; Kong AN Curr Drug Metab; 2002 Oct; 3(5):481-90. PubMed ID: 12369894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]